$ADHD to Participate in Piper Jaffray 27th Annual Healthcare Conference

0
682

Alcobra Ltd. to Participate in Piper Jaffray 27th Annual Healthcare Conference

 Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced participation in a panel titled “Underdiscovered NeuroInnovators” at the Piper Jaffray 27th Annual Healthcare Conference.
Piper Jaffray 27th Annual Healthcare Conference
Panel Title: “Underdiscovered NeuroInnovators”
Date: Wednesday, December 2
Time: 10:00am ET
Location: Lotte New York Palace, New York, NY
Presenter: Dr. Tomer Berkovitz, CFO

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

Contact:
U.S. Investor Contacts
LifeSci Advisors, LLC
Michael Rice
646-597-6979
mrice@lifesciadvisors.com
Media Inquiries
Sam Brown, Inc.
Mike Beyer
312-961-2502
mikebeyer@sambrown.com
Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
debbie@alcobra-pharma.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here